Portola Pharmaceuticals (PTLA:NASDAQ) Investor Relations Material

Overview

Portola Pharmaceuticals is a promising biopharmaceutical company dedicated to developing innovative product candidates that could revolutionize the treatment of thrombosis and other hematologic diseases. The company has gained widespread recognition in the industry for its groundbreaking research efforts and commitment to delivering novel therapies to patients in need. With a strong pipeline of potential products and a talented team of researchers, Portola Pharmaceuticals is poised for continued success and growth in the coming years. Investors and analysts alike are closely watching the company's progress, as its innovative therapies have the potential to transform the field of hematology and improve the lives of millions of patients worldwide.

Frequently Asked Questions

What is Portola Pharmaceuticals's ticker?

Portola Pharmaceuticals's ticker is PTLA

What exchange is Portola Pharmaceuticals traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Portola Pharmaceuticals's headquarters?

They are based in San Francisco, California

How many employees does Portola Pharmaceuticals have?

There are 51-200 employees working at Portola Pharmaceuticals

What is Portola Pharmaceuticals's website?

It is http://www.portola.com

What type of sector is Portola Pharmaceuticals?

Portola Pharmaceuticals is in the Healthcare sector

What type of industry is Portola Pharmaceuticals?

Portola Pharmaceuticals is in the Biotechnology industry

Who are Portola Pharmaceuticals's peers and competitors?

The following five companies are Portola Pharmaceuticals's industry peers:

- Iterum Therapeutics plc

- IXICO plc

- Guardant Health

- Rhythm Pharmaceuticals

- HOOKIPA Pharma